Josef S Smolen Selected Research

Rheumatic Diseases (Rheumatism)

1/2021	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis.
1/2020	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?
1/2020	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
1/2019	Era of biosimilars in rheumatology: reshaping the healthcare environment.
1/2019	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
1/2018	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
1/2018	Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases.
6/2017	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
6/2017	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
6/2015	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Josef S Smolen Research Topics

Disease

178	Rheumatoid Arthritis 10/2022 - 03/2002
41	Arthritis (Polyarthritis) 07/2022 - 01/2002
40	Necrosis 07/2022 - 04/2003
29	Psoriatic Arthritis 01/2022 - 07/2002
25	Rheumatic Diseases (Rheumatism) 01/2021 - 01/2007
25	Inflammation (Inflammations) 01/2019 - 03/2002
21	Pain (Aches) 11/2021 - 11/2002
20	Infections 01/2022 - 11/2004
17	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021 - 01/2002
9	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 03/2002
7	Fatigue 12/2020 - 03/2012
7	Ankylosing Spondylitis 11/2020 - 07/2002
6	Herpes Zoster 01/2022 - 01/2019
6	Lupus Nephritis 01/2020 - 10/2004
6	Joint Diseases (Joint Disease) 01/2020 - 04/2003
6	Neoplasms (Cancer) 01/2019 - 06/2010
6	Bone Resorption 01/2010 - 07/2002
5	Synovitis 01/2021 - 01/2008
5	Disease Progression 09/2019 - 11/2002
5	Pneumonia (Pneumonitis) 01/2017 - 11/2004
4	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2020 - 11/2012
4	Chronic Disease (Chronic Diseases) 09/2019 - 01/2017
3	Proteinuria 01/2020 - 10/2004
3	Osteoarthritis 01/2020 - 09/2007
3	Nephritis 01/2017 - 10/2004
3	Mixed Connective Tissue Disease (MCTD) 07/2011 - 08/2005
3	Systemic Scleroderma (Systemic Sclerosis) 05/2008 - 08/2005
2	Sacroiliitis 07/2022 - 03/2004
2	Experimental Arthritis 01/2020 - 01/2010
2	Hepatitis 01/2020 - 06/2011
2	Virus Diseases (Viral Diseases) 01/2019 - 11/2004
2	Alopecia (Baldness) 01/2019 - 06/2004
2	Arthralgia (Joint Pain) 01/2019 - 06/2015

Drug/Important Bio-Agent (IBA)

53	Methotrexate (Mexate)FDA LinkGeneric 10/2022 - 10/2004
43	Antirheumatic Agents (DMARD)IBA 01/2022 - 04/2002
38	Biological ProductsIBA 01/2022 - 08/2005
27	Adalimumab (Humira)FDA Link 01/2021 - 04/2003
27	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2016 - 03/2002
25	Infliximab (Remicade)FDA Link 12/2021 - 10/2004
19	baricitinibIBA 01/2022 - 01/2014
19	AutoantibodiesIBA 01/2019 - 03/2002
18	GlucocorticoidsIBA 01/2022 - 02/2005
17	tocilizumab (atlizumab)FDA Link 01/2022 - 12/2007
17	Biosimilar PharmaceuticalsIBA 01/2021 - 03/2013
17	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 01/2003
16	Etanercept (Enbrel)FDA Link 01/2020 - 05/2005
14	C-Reactive ProteinIBA 01/2022 - 07/2002
13	CytokinesIBA 07/2022 - 11/2002
11	Abatacept (Orencia)FDA Link 01/2021 - 07/2007
11	tofacitinibIBA 01/2021 - 01/2014
10	Rituximab (Mabthera)FDA Link 01/2021 - 07/2007
10	Leflunomide (Arava)FDA LinkGeneric 01/2020 - 06/2004
10	golimumab FDA Link 01/2020 - 07/2009
9	ametantrone (HAQ)IBA 11/2021 - 04/2007
9	AntibodiesIBA 01/2021 - 08/2005
9	Certolizumab Pegol FDA Link 01/2020 - 11/2009
8	Janus Kinase InhibitorsIBA 01/2022 - 01/2017
7	Interleukin-6 (Interleukin 6)IBA 07/2022 - 03/2008
6	InterleukinsIBA 07/2022 - 06/2012
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 02/2006
6	Rheumatoid FactorIBA 01/2018 - 11/2002
5	apremilastIBA 01/2022 - 01/2014
5	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 09/2015
5	Janus KinasesIBA 10/2020 - 06/2017
5	Acute-Phase Proteins (Acute-Phase Protein)IBA 01/2020 - 01/2005
5	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2020 - 06/2004
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2002
5	Prostaglandins AIBA 01/2020 - 09/2012
4	Interleukin-1 (Interleukin 1)IBA 07/2022 - 12/2003
4	Interleukin-12 (IL 12)IBA 01/2022 - 01/2005
4	Pharmaceutical PreparationsIBA 01/2022 - 05/2011
4	upadacitinibIBA 01/2021 - 12/2016
4	ixekizumabIBA 12/2020 - 01/2020
4	secukinumabIBA 01/2020 - 09/2015
4	ElementsIBA 08/2017 - 08/2007
4	Monoclonal AntibodiesIBA 03/2017 - 11/2004
4	CollagenIBA 01/2015 - 07/2002
4	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 04/2013 - 12/2007
4	AutoantigensIBA 12/2007 - 03/2002
4	OsteoprotegerinIBA 02/2004 - 03/2002
3	amsonic acid (DAS)IBA 01/2020 - 11/2012
3	Anti-Citrullinated Protein AntibodiesIBA 01/2018 - 09/2010
3	pristane (pristan)IBA 01/2017 - 12/2007
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 05/2008
3	Immunoglobulins (Immunoglobulin)IBA 06/2011 - 12/2007
3	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 01/2006 - 07/2002
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2019
2	EnzymesIBA 01/2021 - 06/2004
2	Peptides (Polypeptides)IBA 01/2021 - 01/2010
2	Antinuclear AntibodiesIBA 01/2021 - 02/2016
2	clazakizumabIBA 01/2020 - 06/2017
2	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2019
2	guselkumabIBA 01/2020 - 05/2017
2	sarilumabIBA 01/2020 - 06/2017
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2019 - 01/2014
2	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2017

Therapy/Procedure

93	Therapeutics 10/2022 - 01/2002
6	Aftercare (After-Treatment) 11/2018 - 07/2009
3	Drug Therapy (Chemotherapy) 03/2012 - 07/2004
2	Drug Tapering 01/2019 - 01/2019